The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome

REFERENCES

• The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the international dry eye workshop. Ocul Surf. 2007;5(2):75–92. https://www.ncbi.nlm.nih.gov/pubmed/17508116
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–326.
   PubMed Web of Science ®Google Scholar
• Schaumberg DA, Dana R, Buring JE, et al. Prevalence of dry eye disease among us men: Estimates from the physicians’ health studies. Arch Ophthalmol. 2009;127(6):763–768.
   PubMedGoogle Scholar
• Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: A conceptual framework and preliminary assessment. Cornea. 2004;23(8):751–761.
   PubMed Web of Science ®Google Scholar
• Yamada M, Mizuno Y, Shigeyasu C. Impact of dry eye on work productivity. Clin Outcomes Res CEOR. 2012;4:307–312.
   PubMedGoogle Scholar
• Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: A decision tree analysis. Cornea. 2011;30(4):379–387.
   PubMed Web of Science ®Google Scholar
• Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78(3):409–416.
   PubMed Web of Science ®Google Scholar
• Stapleton F, Garrett Q, Chan C, et al. The epidemiology of dry eye disease. In: Chan C, ed. Dry Eye. Essentials in Ophthalmology. Springer-Verlag, Berlin; 2015:21–29.
   Google Scholar
• Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: Homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012;31(3):271–285.
   PubMed Web of Science ®Google Scholar
• Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. Int Rev Immunol. 2013;32(1):19–41.
   PubMed Web of Science ®Google Scholar
• Wei Y, Asbell PA. The core mechanism of dry eye disease is inflammation. Eye Contact Lens Sci Clin Pract. 2014;40(4):248–256.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: An immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130(1):90–100.
   PubMedGoogle Scholar
• Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):163–178. https://www.ncbi.nlm.nih.gov/pubmed/17508120
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol. 2008;71(6):89–95.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease 1. Ophthalmology. 2000;107(4):631–639.
   PubMed Web of Science ®Google Scholar
• Pinto-Fraga J, López-Miguel A, González-García MJ, et al. Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: A randomized controlled clinical trial. Ophthalmology. 2016;123(1):141–153.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337–342.
   PubMed Web of Science ®Google Scholar
• Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136–142.
   PubMedGoogle Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–1723.
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M. Glucocorticoids and chronic inflammation. Rheumatol Oxf Engl. 2016;55(suppl 2):ii6–ii14.
   PubMed Web of Science ®Google Scholar
• Ej H, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: Results of a Phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60.
   PubMed Web of Science ®Google Scholar
• Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207–215.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245–254.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: Are they all the same? Ophthalmol Ther. 2013;2(2):55–72.
   PubMedGoogle Scholar
• Prabhasawat P, Tseng SCG. Frequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol. 1998;82(6):666–675.
   PubMed Web of Science ®Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome1. Ophthalmology. 1999;106(4):811–816.
   PubMed Web of Science ®Google Scholar
• Hong S, Kim T, Chung S-H, et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren’s syndrome. J Ocul Pharmacol Ther. 2007;23(1):78–82.
   PubMed Web of Science ®Google Scholar
• Lee JH, Min K, Kim SK, et al. Inflammatory cytokine and osmolarity changes in the tears of dry eye patients treated with topical 1% methylprednisolone. Yonsei Med J. 2014;55(1):203.
   PubMed Web of Science ®Google Scholar
• Byun Y, Kim T, Kwon SM, et al. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2012;31(5):509–513.
   PubMed Web of Science ®Google Scholar
• Leibowitz HM, Kupferman A. Anti-inflammatory effectiveness in the cornea of topically administered prednisolone. Invest Ophthalmol Vis Sci. 1974;13(10):757–763.
   Google Scholar
• Lee HK, Ryu IH, Seo KY, et al. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology. 2006;113(2):198–205.
   PubMed Web of Science ®Google Scholar
• Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991;10(10):933–937.
   PubMed Web of Science ®Google Scholar
• The Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol. 1999;127(5):537–544.
   PubMed Web of Science ®Google Scholar
• Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest. 1984;74(5):1803–1810.
   PubMed Web of Science ®Google Scholar
• Bucala R, Gallati M, Manabe S, et al. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res. 1985;40(6):853–863.
   PubMed Web of Science ®Google Scholar
• Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92(4):455–459.
   PubMed Web of Science ®Google Scholar
• Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9(2):157–165.
   PubMedGoogle Scholar
• Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33(4):532–552.
   PubMed Web of Science ®Google Scholar
• Novack GD, Howes J, Crockett RS, et al. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7(4):266–269.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–457.
   PubMed Web of Science ®Google Scholar
• Villani E, Garoli E, Termine V, et al. Corneal confocal microscopy in dry eye treated with corticosteroids. Optom Vis Sci Off Publ Am Acad Optom. 2015;92(9):e290–295.
   PubMed Web of Science ®Google Scholar
• Kheirkhah A, Dohlman TH, Amparo F, et al. Effects of corneal nerve density on the response to treatment in dry eye disease. Ophthalmology. 2015;122(4):662–668.
   PubMed Web of Science ®Google Scholar
• Boynton GE, Raoof D, Niziol LM, et al. Prospective randomized trial comparing efficacy of topical loteprednol etabonate 0.5% versus cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation. Cornea. 2015;34(7):725–732.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Donnenfeld ED, Holland EJ, et al. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%. Eye Contact Lens. 2014;40(5):289–296.
   PubMed Web of Science ®Google Scholar
• Jung HH, Ji YS, Sung MS, et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjögren’s syndrome. Chonnam Med J. 2015;51(1):26–32.
   PubMedGoogle Scholar
• Schopf L, Enlow E, Popov A, et al. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol Ther. 2014;3(1–2):63–72.
   PubMedGoogle Scholar
• Kupferman A, Leibowitz HM. Penetration of fluorometholone into the cornea and aqueous humor. Arch Ophthalmol Chic Ill 1960. 1975;93(6):425–427.
   PubMedGoogle Scholar
• McGhee CNJ, Watson DG, Midgley JM, et al. Penetration of synthetic corticosteroids into human aqueous humour. Eye. 1990;4(3):526–530.
   PubMedGoogle Scholar
• Iqbal Z, Watson DG, Midgley JM, et al. The metabolism of fluorometholone by bovine cornea. J Pharm Biomed Anal. 1993;11(11–12):1115–1120.
   PubMed Web of Science ®Google Scholar
• Leibowitz HM, Hyndiuk RA, Lindsey C, et al. Fluorometholone acetate: Clinical evaluation in the treatment of external ocular inflammation. Ann Ophthalmol. 1984;16(12):1110–1115.
   PubMedGoogle Scholar
• Trinavarat A, Atchaneeyasakul L-O, Surachatkumtonekul T, et al. Comparison of topical prednisolone acetate, ketorolac tromethamine and fluorometholone acetate in reducing inflammation after phacoemulsification. J Med Assoc Thail Chotmaihet Thangphaet. 2003;86(2):143–150.
   PubMedGoogle Scholar
• Morrison E, Archer DB. Effect of fluorometholone (FML) on the intraocular pressure of corticosteroid responders. Br J Ophthalmol. 1984;68(8):581–584.
   PubMed Web of Science ®Google Scholar
• Stewart RH, Smith JP, Rosenthal AL. Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res. 1984;3(6):835–839.
   PubMed Web of Science ®Google Scholar
• Kass M, Cheetham J, Duzman E, et al. The ocular hypertensive effect of 0.25% fluorometholone in corticosteroid responders. Am J Ophthalmol. 1986;102(2):159–163.
   PubMed Web of Science ®Google Scholar
• Lin T, Gong L. Topical fluorometholone treatment for ocular dryness in patients with Sjögren syndrome: A randomized clinical trial in China. Medicine (Baltimore). 2015;94(7):e551.
   PubMed Web of Science ®Google Scholar
• Yang C, Sun W, Gu Y. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 2006;7(8):675–678.
   PubMedGoogle Scholar
• Avunduk AM, Avunduk MC, Varnell ED, et al. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: A clinical and immunocytochemical study. Am J Ophthalmol. 2003;136(4):593–602.
   PubMed Web of Science ®Google Scholar
• Jee D, Park M, Lee HJ, et al. Comparison of treatment with preservative-free versus preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome. J Cataract Refract Surg. 2015;41(4):756–763.
   PubMed Web of Science ®Google Scholar
• Kim Y-H, Jung J-C, Jung S-Y, et al. Comparison of the efficacy of fluorometholone with and without benzalkonium chloride in ocular surface disease. Cornea. 2016;35(2):234–242.
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhang C, Chuck RS. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model. Mol Vis. 2012;18:1803–1812.
   PubMed Web of Science ®Google Scholar
• Park CY, Zhuang W, Lekhanont K, et al. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model. Mol Vis. 2007;13:2222–2232.
   PubMed Web of Science ®Google Scholar
• Lekhanont K, Leyngold IM, Suwan-Apichon O, et al. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin b-induced mouse model. Cornea. 2007;26(1):84–89.
   PubMed Web of Science ®Google Scholar
• Moore QL, De Paiva CS, Pflugfelder SC. Effects of dry eye therapies on environmentally induced ocular surface disease. Am J Ophthalmol. 2015;160(1):135–142.e1.
   PubMed Web of Science ®Google Scholar
• Jonisch J, Steiner A, Udell IJ. Preservative-free low-dose dexamethasone for the treatment of chronic ocular surface disease refractory to standard therapy. Cornea. 2010;29(7):723–726.
   PubMed Web of Science ®Google Scholar
• Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: Results of a randomized clinical trial. Clin Ophthalmol Auckl NZ. 2011;5:633–643.
   PubMedGoogle Scholar
• Leibowitz HM, Bartlett JD, Rich R, et al. Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol Chic Ill 1960. 1996;114(8):933–937.
   PubMedGoogle Scholar
• Yaylali V, Ozbay D, Tatlipinar S, et al. Efficacy and safety of rimexolone 1% versus prednisolone acetate 1% in the control of postoperative inflammation following phacoemulsification cataract surgery. Int Ophthalmol. 2004;25(1):65–68.
   PubMedGoogle Scholar
• Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: An update. Clin Ophthalmol Auckl NZ. 2011;5:811–816.
   PubMedGoogle Scholar
• Jamal KN, Callanan DG. The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol Auckl NZ. 2009;3:381–390.
   PubMedGoogle Scholar
• Wilson ME, O’Halloran H, VanderVeen D, et al. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: A randomized safety and efficacy study. Eye. 2016;30(9):1187–1194.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Papa V, Milazzo G, et al. Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. Cornea. 2002;21(5):476–481.
   PubMed Web of Science ®Google Scholar
• Eilon LA, Walker SR. Clinical evaluation of clobetasone butyrate eye drops in the treatment of anterior uveitis and its effects on intraocular pressure. Br J Ophthalmol. 1981;65(9):644–647.
   PubMed Web of Science ®Google Scholar
• Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndrome. Eur J Ophthalmol. 2013;23(3):368–376.
   PubMed Web of Science ®Google Scholar
• Rastogi RK, Mathur A, Raizada IN. Efficacy of medrysone as anti-inflammatory agent. Indian J Ophthalmol. 1985;33(5):295.
   PubMedGoogle Scholar
• Mindel JS, Tavitian HO, Smith H, et al. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol Chic Ill 1960. 1980;98(9):1577–1578.
   PubMedGoogle Scholar
• Craig CR, Stitzel RE. Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins, Baltimore, MD; 2004.
   Google Scholar
• Leopold IH, Sawyer JL, Green H. Intraocular penetration of locally applied steroids. AMA Arch Ophthalmol. 1955;54(6):916–921.
   PubMedGoogle Scholar
• Eadie S, Thompson M. Kerato-conjunctivitis sicca treated with cortisone and ACTH. Br J Ophthalmol. 1955;39(2):90–97.
   PubMedGoogle Scholar
• Nichols J, Snyder RW. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol. 1998;9(4):40–44.
   PubMedGoogle Scholar
• Flach AJ. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans Am Ophthalmol Soc. 2001;99:205–212.
   PubMedGoogle Scholar
• Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review. Drug Saf. 2002;25(4):233–250.
   PubMed Web of Science ®Google Scholar
• Aragona P, Stilo A, Ferreri F, et al. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren’s syndrome patients. Eye Lond Engl. 2005;19(5):535–539.
   PubMed Web of Science ®Google Scholar
• Bourcier T, Acosta MC, Borderie V, et al. Decreased corneal sensitivity in patients with dry eye. Invest Ophthalmol Vis Sci. 2005;46(7):2341–2345.
   PubMed Web of Science ®Google Scholar